satur
arteri
blood
oxygen
partial
pressureoxygen
concentr
mmhg
age
sex
comorbid
clinic
laboratori
paramet
patient
admiss
shown
supplementari
tabl
three
patient
die
hospit
patient
success
discharg
oxygen
therapi
antivir
therapi
ainterferon
kaletra
lopinavirritonavir
immunoenhanc
therapi
thymosin
prevent
bacteri
infect
reliev
cough
elimin
phlegm
nutrit
support
commonli
use
patient
receiv
extra
lowdos
methylprednisolon
treatment
dosag
mgkgday
day
via
intraven
inject
specif
dosag
durat
methylprednisolon
patient
determin
accord
clinic
manifest
leukocyt
count
lymphocyt
count
inflammatori
index
lesion
rang
signific
differ
age
sex
comorbid
clinic
laboratori
paramet
two
group
supplementari
data
tabl
median
spo
rest
admiss
similar
two
group
patient
receiv
oxygen
therapi
dynam
chang
spo
shown
fig
patient
methylprednisolon
treatment
faster
improv
spo
moreov
patient
without
methylprednisolon
treatment
significantli
longer
interv
use
supplement
oxygen
therapi
methylprednisolon
treatment
day
interquartil
rang
iqr
vs
day
iqr
p
regard
intens
level
oxygen
support
patient
receiv
methylprednisolon
treatment
less
like
develop
receiv
mechan
ventil
p
patient
without
methylprednisolon
treatment
develop
receiv
mechan
ventil
noninvas
ventil
niv
imv
invas
ventil
imv
extracorpor
membran
oxygen
ecmo
patient
methylprednisolon
treatment
develop
receiv
mechan
ventil
nmv
imv
imv
ecmo
laboratori
test
perform
everi
day
methylprednisolon
treatment
associ
faster
decreas
creactiv
protein
fig
signific
differ
observ
inflammatori
index
supplementari
fig
two
death
occur
patient
methylprednisolon
treatment
one
patient
without
methylprednisolon
treatment
signific
differ
mortal
rate
observ
two
group
p
addit
length
icu
hospit
significantli
shorter
patient
methylprednisolon
treatment
day
iqr
vs
day
iqr
p
fig
fig
term
chest
ct
scan
day
absorpt
degre
focu
significantli
better
patient
methylprednisolon
treatment
fig
methylprednisolon
treatmentinduc
complic
anoth
major
concern
common
complic
caus
methylprednisolon
secondari
infect
experi
secondari
infect
occur
sever
patient
pneumonia
sensit
fulldos
antibacteri
drug
immedi
ad
secondli
use
immun
regul
human
immunoglobulin
enhanc
patient
immun
function
experi
human
immunoglobulin
usual
use
critic
patient
dosag
gday
day
puls
therapi
thirdli
thymosin
secret
thymic
epitheli
cell
promot
matur
tlymphocyt
regul
function
cellular
immun
suggest
use
thymosin
hospit
cours
treatment
determin
accord
result
lymphocyt
test
benefit
condit
monitor
refin
manag
seriou
methylprednisolon
treatmentinduc
complic
observ
present
cohort
conclus
earli
lowdos
shortterm
applic
methylprednisolon
associ
better
clinic
outcom
sever
patient
pneumonia
consid
occurr
ard
nevertheless
futur
random
control
trial
desper
need
confirm
find
studi
midand
longterm
outcom
discharg
data
use
support
find
studi
includ
within
articl
supplementari
materi
